zoledronic acid has been researched along with Cancer of Jaw in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bohle, GC; Carlson, DL; Estilo, CL; Farooki, A; Fornier, M; Halpern, JL; Huryn, JM; Lwin, PT; Riedel, ER; Schoder, H; Tunick, SJ; Van Poznak, CH; Wiliams, T; Zhou, Q | 1 |
| Enomoto, Y; Fujimura, T; Fukuhara, H; Hirano, Y; Homma, Y; Igawa, Y; Ishikawa, A; Kume, H; Miyazaki, H; Nishimatsu, H; Suzuki, M | 1 |
2 other study(ies) available for zoledronic acid and Cancer of Jaw
| Article | Year |
|---|---|
Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Jaw; Jaw Neoplasms; Male; Mandible; Maxilla; Osteonecrosis; Pamidronate; Retrospective Studies; Risk Factors; Treatment Outcome; Zoledronic Acid | 2008 |
Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer treated using zoledronic acid and docetaxel.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Docetaxel; Drug Therapy, Combination; Humans; Imidazoles; Incidence; Japan; Jaw Neoplasms; Leukopenia; Male; Middle Aged; Osteonecrosis; Prognosis; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Taxoids; Zoledronic Acid | 2012 |